Active, not recruitingPhase 2NCT05741060

Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Akira Sekikawa
Principal Investigator
Akira Sekikawa, MD, PhD, PhD
University of Pittsburgh
Intervention
S-equol(drug)
Enrollment
369 target
Eligibility
65-85 years · All sexes
Timeline
20232027

Study locations (3)

Collaborators

National Institute on Aging (NIA)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05741060 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials